Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Raymond James Financial

Investment analysts at Raymond James Financial assumed coverage on shares of Compass Therapeutics (NASDAQ:CMPX - Get Free Report) in a report released on Tuesday. The firm set an "outperform" rating and a $9.00 price target on the stock. Raymond James Financial's target price suggests a potential upside of 246.15% from the stock's previous close.

Several other analysts also recently weighed in on CMPX. Wedbush restated an "outperform" rating and set a $8.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Leerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 1st. Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $4.00 to $6.00 in a research report on Wednesday, April 2nd. HC Wainwright reaffirmed a "buy" rating and set a $24.00 target price on shares of Compass Therapeutics in a research report on Monday, April 21st. Finally, Guggenheim cut their target price on shares of Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $12.67.

Compass Therapeutics Stock Up 1.6%

NASDAQ:CMPX opened at $2.60 on Tuesday. The company's 50 day moving average is $2.17 and its 200-day moving average is $2.27. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $4.08. The firm has a market cap of $359.53 million, a price-to-earnings ratio of -6.34 and a beta of 1.42.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). Research analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Insider Transactions at Compass Therapeutics

In related news, insider Jonathan Anderman acquired 20,000 shares of the firm's stock in a transaction on Monday, April 7th. The shares were bought at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider owned 21,000 shares of the company's stock, valued at $32,340. This trade represents a 2,000.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. 29.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its holdings in Compass Therapeutics by 298.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after purchasing an additional 12,917 shares during the last quarter. Independent Advisor Alliance acquired a new stake in shares of Compass Therapeutics during the fourth quarter worth approximately $26,000. BNP Paribas Financial Markets bought a new position in shares of Compass Therapeutics in the fourth quarter valued at approximately $27,000. Mariner LLC bought a new position in shares of Compass Therapeutics in the fourth quarter valued at approximately $30,000. Finally, Strs Ohio acquired a new position in shares of Compass Therapeutics in the 1st quarter worth approximately $34,000. Institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.